Results 261 to 270 of about 87,208 (292)

Rectal cancer: Neoadjuvant chemoradiotherapy

Best Practice & Research Clinical Gastroenterology, 2016
The monolithic approach to apply the same schedule of preoperative 5-fluorouracil (5-FU)- or capecitabine-based chemoradiotherapy (CRT) to all patients with clinically staged TNM stage II/III rectal cancer need to be questioned. Five randomized trials have been completed to determine if the addition of oxaliplatin to preoperative 5-FU/capecitabine ...
Claus, Rödel, Ralf, Hofheinz, Emmanouil, Fokas   +2 more
openaire   +2 more sources

Rationale for chemoradiotherapy

International Journal of Clinical Oncology, 2004
The rationale for combining chemotherapy (CT) and radiotherapy (RT) is based mainly on two ideas, one being spatial cooperation and the other the enhancement of radiation effects. Spatial cooperation is effective if CT is sufficiently active to eradicate subclinical metastases and if the primary local tumor is effectively treated by RT. In this regard,
openaire   +2 more sources

Chemoradiotherapy for gastrointestinal cancers

Current Oncology Reports, 2005
New combinations of chemotherapy with radiotherapy for gastrointestinal cancers are showing evidence that improved outcomes may result from toxicity profiles associated with "targeted" systemic radiosensitizing agents. These new agents are also clinically attractive owing to such factors as oral bioavailability and patient dosing schedules, making them
Tyvin A, Rich, Christopher, Crane, Joshua D, Lawson, Jerome, Landry   +3 more
openaire   +2 more sources

Hip complications following chemoradiotherapy

Clinical Oncology, 1995
Chemoradiotherapy protocols are a recent development in the management of tumours where preservation of organ function is important. It is now recognized that such combined treatment may produce adverse effects below the accepted dose thresholds for either modality.
P J, Jenkins, D J, Montefiore, S J, Arnott   +2 more
openaire   +2 more sources

Prodrugs in Genetic Chemoradiotherapy

Current Pharmaceutical Design, 2003
Improvements in the radiotherapeutic management of solid tumors through the concurrent use of gene therapy is a realistic possibility. Of the broad array of candidate genes that have been evaluated, those encoding prodrug-activating enzymes are particularly appealing since they directly complement ongoing clinical chemoradiation regimes.
Adam V, Patterson, Mark P, Saunders, Olga, Greco   +2 more
openaire   +2 more sources

Stage III: Definitive Chemoradiotherapy

2009
Concurrent chemoradiotherapy is presently the standard treatment for stage III inoperable non-small cell lung cancer. Within this treatment framework, conventionally fractionated radiotherapy to a total dose of 60-66 Gy has proven effective. The chemotherapy should be performed using a cisplatin-based regimen or, if contraindicated, carboplatin.
Rainer, Fietkau, Sabine, Semrau
openaire   +2 more sources

Chemoradiotherapy for cervical cancer

European Journal of Cancer, 2002
Cervical cancer remains a major health problem worldwide, despite advances in screening. For patients with locally advanced stage disease, failure to obtain local-regional control usually results in death. In an effort to improve local-regional tumour control, neoadjuvant and concurrent chemoradiation has been tested.
openaire   +2 more sources

Chemoradiotherapy for lung cancer

Expert Opinion on Pharmacotherapy, 2005
Chemoradiotherapy is a standard treatment for both unresectable locally advanced non-small cell lung cancer and limited-stage small cell lung cancer. Cisplatin-based chemotherapy with concurrent thoracic radiotherapy yields a 5-year survival rate of approximately 15% for patients with unresectable locally advanced non-small cell lung cancer.
openaire   +2 more sources

Chemoradiotherapy: Emerging treatment improvement strategies

Head & Neck, 2002
AbstractBackground.The use of chemotherapeutic drugs in combination with radiotherapy has become a common strategy for the treatment of advanced cancer. Solid evidence exists showing that chemotherapy administered during the course of radiotherapy (concurrent chemoradiotherapy) increases both local tumor control and patient survival in a number of ...
Luka, Milas, Kathryn A, Mason, Zhongxing, Liao, Kian K, Ang   +3 more
openaire   +2 more sources

Chemoradiotherapy for unresectable pancreatic cancer

International Journal of Clinical Oncology, 2008
Treatment options for unresectable pancreatic cancer, including concurrent chemoradiotherapy, chemotherapy alone, and chemotherapy followed by chemoradiotherapy, are largely ineffective and result in a median survival of approximately 10-12 months. Although quality data on the benefit of radiotherapy in unresectable pancreatic cancer are lacking, it ...
Edgar, Ben-Josef, Theodore S, Lawrence
openaire   +2 more sources